share_log

CRISPR Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144

CRISPR Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144

CRISPR Therapeutics | 144:拟议出售证券
SEC announcement ·  03/22 16:03
Moomoo AI 已提取核心信息
CRISPR Therapeutics officer Phuong Khanh Morrow is set to sell 50,767 shares of the company's common stock on 03/22/2024, as per the latest filings. The shares, valued at approximately $3,699,269.45, were acquired on the same date through the exercise of stock options. The transaction involved a cash payment to the issuer for the securities. This sale comes without any reported transactions by Morrow in the past three months.
CRISPR Therapeutics officer Phuong Khanh Morrow is set to sell 50,767 shares of the company's common stock on 03/22/2024, as per the latest filings. The shares, valued at approximately $3,699,269.45, were acquired on the same date through the exercise of stock options. The transaction involved a cash payment to the issuer for the securities. This sale comes without any reported transactions by Morrow in the past three months.
根据最新文件,CRISPR Therapeutics高管Phuong Khanh Morrow定于2024年3月22日出售该公司50,767股普通股。这些股票的价值约为3,699,269.45美元,是同日通过行使股票期权收购的。该交易涉及向发行人支付证券的现金。在过去的三个月中,Morrow没有报告任何交易。
根据最新文件,CRISPR Therapeutics高管Phuong Khanh Morrow定于2024年3月22日出售该公司50,767股普通股。这些股票的价值约为3,699,269.45美元,是同日通过行使股票期权收购的。该交易涉及向发行人支付证券的现金。在过去的三个月中,Morrow没有报告任何交易。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息